Navigation Links
Ted Karkus Appointed Interim Chief Executive Officer Of The Quigley Corporation
Date:6/18/2009

DOYLESTOWN, Pa., June 18 /PRNewswire-FirstCall/ -- The Quigley Corporation, (Nasdaq: QGLY), www.quigleyco.com, today announced that Ted Karkus, Chairman of the Board of The Quigley Corporation, has been appointed Interim Chief Executive Officer by the Board of Directors of the Company. Mr. Karkus will serve in this role effective June 18, 2009 and will be compensated at a rate of $5,000 per week for his services.

Mr. Karkus will temporarily assume the duties and responsibilities of Interim Chief Executive Officer while the Board of Directors reviews the Company's operations and staffing at the executive management level.

This appointment may be terminated by the Board of Directors at any time.

About The Quigley Corporation

The Quigley Corporation (Nasdaq: QGLY, http://www.Quigleyco.com) is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufacturer of the COLD-EEZE(R) family of lozenges, gums and sugar free tablets clinically proven to cut the common cold nearly in half. COLD-EEZE customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation has several wholly owned subsidiaries; Quigley Manufacturing Inc. consists of two FDA approved facilities to manufacture COLD-EEZE(R) lozenges as well as fulfill other contract manufacturing opportunities. Quigley Pharma Inc. (http://www.QuigleyPharma.com) conducts research in order to develop and commercialize a pipeline o
'/>"/>

SOURCE The Quigley Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Ted Karkus and Karkus Slate of Directors Prevail in Federal Court, Seated as Directors of The Quigley Corporation; Ted Karkus Elected Chairman of the Board
2. Ted Karkus Admits to Financial Relationship With Dr. Richard A. Rosenbloom; Demonstrates Pattern of Improper Influence, Unethical Behavior, Falsification and Distortion; Company Questions What Else Karkus May Be Hiding From Shareholders
3. Dissident Stockholder Ted Karkus Found to Have Undisclosed Financial Arrangements With Dr. Richard A. Rosenbloom, COO Of Quigley Pharma, From 2008 to Date of Proxy: Rosenbloom Suspended Without Pay Pending Further Investigation
4. Karkus Nominees Caution Quigley Shareholders Not to be Fooled by the Companys Latest Announcement
5. Judge Rejects Quigleys Claims - Karkus Director Candidates Prevail in Federal Court
6. Quigley Corporation Receives Support from Leading Independent Proxy Advisory Firms; RiskMetrics and Glass Lewis Reject Dissident Stockholder Ted Karkus, Citing Failure to Provide Detailed Business Plan
7. The Quigley Corporation Issues Open Letter to Stockholders; Urges Stockholders to Reject Dissident Ted Karkus Solicitation Efforts
8. Netsmarts Haines Reappointed to CCHIT Behavioral Health Work Group
9. Antiabortion Advocate Appointed to Senior Position at HHS
10. President of PRN Funding Appointed to Factoring Association Advisory Board
11. Dr. James Hevezi Appointed as Chief Physicist for CyberKnife Center of Miami
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of ... area has treated just about every type of injury that ... And for those same twenty-plus years, the team at Doctors ... with the best possible doctor. With the combined breadth ...
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved ... upcoming 32nd Annual Miami Breast Cancer Conference ... LLC (PER®) , shares that “a fast-growing, virulent” cancer ... she had not followed up her clean mammogram with ...
(Date:1/22/2015)... Calif. (PRWEB) January 22, 2015 ... Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were ... their leadership in advancing biotechnology, biomedical science, medical ... and Olsen each received the “2014 Life Sciences ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 IsoComforter, Inc. has ... machine with patented IsoTube design to treat specific body parts ... the most progressive and easy to use patented cold therapy ... and sports related orthopedic and muscle injuries. IsoComforter has ...
(Date:1/22/2015)... Payday lending practices in four southern states worsen ... to the states that permit them, according to a ... Race and Wealth. , While they generate hundreds of ... the same time substantially depress economic activity, according to ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2
... us are counting,down the days leading up to the ... Council of America reminds you that time is running ... your flexible spending,account., Made available through employers, flexible ... pay for out-of-pocket health expenses,such as an eye exam ...
... CEO, Will Continue Serving as Chairman of the Board, ... Bulletin Board: MLSS), the recognized leader in,advanced injection technologies, ... Martin, Chief Executive Officer of the Company,s,medical division, as ... of its Board,of Directors, effective January 1, 2008. As ...
... A study led by Massachusetts General Hospital (MGH) researchers ... fibrosis (IPF), a usually fatal lung disease for which ... that a specific molecular pathway appears responsible for key ... IPF, the cause of which is currently unknown. ...
... has been shown to improve the sleep quality and ... most commonly-used medication, according to research published today in ... the effects of the new drug dexmedetomidine with the ... pain and anxiety experienced by mechanically ventilated ICU patients ...
... Philadelphia, PA, December 12, 2007 Major depressive disorder ... almost one in five individuals. More than 75% of ... have at least one recurrence, with the majority having ... disability of all medical illnesses, with substantial functional impairment, ...
... the fight against cancer: Recent research at the University ... Ganoderma lucidum aid in suppressing some of the mechanisms ... action of the fungus: disrupting androgen receptor activity and ... the past 3-4 decades much scientific research has dealt ...
Cached Medicine News:Health News:Joe Martin Appointed CEO of Milestone Scientific and New Executive Member of the Board of Directors 2Health News:Joe Martin Appointed CEO of Milestone Scientific and New Executive Member of the Board of Directors 3Health News:Molecular pathway appears crucial in development of pulmonary fibrosis 2Health News:Intensive care quality of sleep improved by new drug, reports study 2Health News:Venlafaxine extended-release effective for patients with major depression 2Health News:Active compounds found in Ganoderma lucidum fungus with potential to treat prostate cancer 2
(Date:1/23/2015)... , Jan. 23, 2015 Cord Blood America, Inc. ... ("CBAI" or the "Company")  filed a Preliminary Proxy Statement, Schedule ... ) today, and provides an update for shareholders detailing why ... is requested. Dear Shareholders, As we ...
(Date:1/23/2015)... (NYSE: MNK ) announced today that its ... The open-ended authorization permits the company to repurchase up ... "Funding additional initiatives and seeking attractive business ... pursue a range of focused growth strategies," said ...
(Date:1/23/2015)... China , Jan. 23, 2015 Tianyin Pharmaceutical ... company that specializes in the development and sale of ... generics and active pharmaceutical ingredients (API) today announced the ... (JCM) API operation. 1. Following the September ...
Breaking Medicine Technology:Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4
... extent of intestinal damage does not explain patients,symptoms, ... have found that capsule endoscopy can provide a ... disease. This new information can,help physicians detect and ... following treatment. These findings are published in,this month,s ...
... Pharmacopeia,(Nasdaq: PCOP ), an innovator in the ... announced the completion of recruitment,in the company,s multi-center ... lead internal product candidate. The objective of the ... the efficacy and safety of 200 and 500 ...
Cached Medicine Technology:Mayo Clinic Finds Capsule Endoscopy Can Detect Intestinal Damage Caused by Celiac Disease 2Mayo Clinic Finds Capsule Endoscopy Can Detect Intestinal Damage Caused by Celiac Disease 3Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA) 2Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA) 3Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA) 4
The new Inferior Medial Orbital Rim Implant (IMORI) provides surgeons with an excellent alternative for patients with a deficient or recessed "tear trough" area often characterized as a look of fatig...
1.5 mm inner cutting edge....
Designed to safely and easily removing a cataract nucleus, round serrated handle, dull finish....
Cross action, round handle, maximum opening 2.8 mm....
Medicine Products: